Clinical Trial Update: Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of zanubrutinib and BGB-11417 in patients previously treated for Waldenström macroglobulinemia to assess effic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• BGB-11417
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: NOT_YET_RECRUITING